natgillin/translations-raw huggingface dataset:
Twenty four patients were treated for 28 days with 150 mg nintedanib twice daily (13 patients received nintedanib on top of chronic treatment with standard doses of pirfenidone; 11 patients received nintedanib alone).
Štiriindvajset bolnikov so 28 dni zdravili z 150 mg nintedaniba dvakrat na dan (13 bolnikov je prejemalo nintedanib poleg kroničnega zdravljenja z običajnimi odmerki pirfenidona, medtem ko je 11 bolnikov prejemalo samo nintedanib).
Twenty mild to moderately immunocompromised children and adolescents 5 through 17 years of age (receiving chemotherapy and/or radiation therapy or who had recently received chemotherapy) were randomized 1:1 to trivalent Fluenz or placebo.
Dvajset otrok in mladostnikov z blago do zmerno imunsko oslabelostjo v starosti od 5 do 17 let (ki so prejemali kemoterapijo in/ali radioterapijo ali ki so pred kratkim prejemali kemoterapijo) je bilo randomiziranih 1:1 na trivalentno cepivo Fluenz ali placebo.
Twenty of the 24 patients who required dialysis at baseline were able to discontinue dialysis during Soliris treatment.
Dvajset od 24 bolnikov, pri katerih je bila v izhodišču potrebna dializa, je lahko med zdravljenjem z zdravilom Soliris dializo prekinilo.
Twenty one (16.3%) had concomitant candidemia.
Enaindvajset (16,3 %) jih je imelo sočasno kandidemijo.
Twenty patients (50%) experienced leukocytosis; however, in all these patients, the WBC count was declining or had normalized by the time of bone marrow remission and cytotoxic chemotherapy or leukopheresis was not required.
Pri dvajsetih bolnikih (50 %) se je pojavila levkocitoza; vendar je pri vseh teh bolnikih število WBC padalo ali se je normaliziralo do remisije kostnega mozga in citotoksična kemoterapija ali levkofereza nista bili potrebni.
Twenty seven (7%) out of 389 patients enrolled in study 301 and 14 (4.1%) out of 342 enrolled in study 302 were not randomised due to a positive mannitol tolerance test (MTT) defined as either 1) a fall in FEV1 >20% from baseline at midpoint (step 4) or 2) fall from baseline > 20 % at end of test that did not recover to < 20% within 15 minutes or 3) who had a fall in FEV1 > 50% from baseline at end of test (step 6) or 4) who had a fall in Sp02 to < 89% during the procedure.
Sedemindvajset (7 %) od 389 preiskovancev, vključenih v študijo 301, in 14 (4,1 %) od 342 preiskovancev, vključenih v študijo 302, ni bilo randomiziranih zaradi pozitivnega testa tolerance na manitol (MTT), opredeljenega kot 1) >20-odstotni upad FEV1 pod izhodiščno raven na sredini študije (4. faza); ali 2) upad za >20 % pod izhodiščno raven na koncu testa, ki se v 15 minutah ni vrnil na raven <20 %; ali 3) >50-odstotni upad FEV1 pod izhodiščno raven na koncu ocene (6. faza); ali 4) upad SpO2 med postopkom na raven <89 %.
Twenty seven (7%) out of 389 patients enrolled in study 301 and 14 (4.1%) out of 342 enrolled in study 302 were not randomised due to a positive mannitol tolerance test (MTT).
Zaradi pozitivnega testa tolerance manitola (MTT) ni bilo randomiziranih 27 (7 %) od 389 preiskovancev, vključenih v študijo 301, in 14 (4,1 %) od 342 preiskovancev, vključenih v študijo
Twenty- four patients had neutropaenia.
24 bolnikov je imelo nevtropenijo.
Twenty-eight (5%) of the 511 patients experienced a fatal infection.
Pri 28 (5 %) od 511 bolnikov se je pojavila okužba s smrtnim izidom.
Twenty-eight of the 231 patients (12.1%) on vandetanib and 3 of the 99 (3.0%) on placebo discontinued treatment because of an adverse event.
Osemindvajset od 231 (12,1 %) prejemnikov vandetaniba in 3 od 99 (3,0 %) prejemnikov placeba je zdravljenje prekinilo zaradi neželenega učinka.
Twenty-five percent of subjects had an ECOG performance status ≥ 2.
Petindvajset odstotkov preiskovancev je imelo ocenjeno stanje zmogljivosti po lestvici ECOG ≥2.
Twenty-one days after the second dose, a 4-fold increase in serum neutralising antibody against A/Indonesia/5/2005 was achieved in 94.4% of subjects aged 18-60 years and in 80.4% of subjects over 60 years of age.
Enaindvajset dni po drugem odmerku je bil dosežen 4-kraten porast titra nevtralizirajočih protiteles v serumu proti A/Indonesia/5/2005 pri 94,4 % preiskovancev, starih od 18 do 60 let, in pri 80,4 % preiskovancev, starejših od 60 let.
Twenty-one days after the second dose, the seroprotection rate and the vaccine response rate in subjects who received the vaccine 12 months apart were 92.0% and 100%, respectively.
Enaindvajset dni po drugem odmerku je bil pri preiskovancih, ki so dobili cepivo v presledku 12 mesecev, delež serološke zaščite proti A/Vietnam/1194/2004 92,0 % in delež odziva na cepivo 100 %.
Twenty-one patients treated with Revestive (48.8%) versus 9 on placebo (20.9%) achieved at least a one day reduction in parenteral nutrition administration (p=0.008).
Enaindvajset bolnikov, zdravljenih z zdravilom Revestive (48,8 %), je doseglo skrajšanje prejemanja parenteralne prehrane za vsaj en dan v primerjavi z 9 bolniki na placebu (20,9 %) (p = 0,008).
Twenty-seven (27, 75%) had undergone a nephrectomy.
Sedemindvajset (27, 75 %) jih je imelo nefrektomijo.
Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4  2.0 weeks) and, in general, efficacy was maintained.
V fazi odprtega podaljška je šestindvajset bolnikov še naprej prejemalo bosentan v nadaljnjem 24-tedenskem obdobju zdravljenja (AC-052-409) študije BREATHE-5 (povprečno trajanje zdravljenja 24,4  2,0 tedna), pri čemer se je učinek na splošno ohranil.
Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4  2.0 weeks) and, in general, efficacy was maintained.
V fazi odprtega podaljška je šestindvajset bolnikov še naprej prejemalo bosentan v nadaljnjem 24-tedenskem obdobju zdravljenja (AC-052-409) študije BREATHE-5 (povprečno trajanje zdravljenja = 24,4  2,0 tedna), pri čemer se je učinek na splošno ohranil.
Twenty-two of 25 (88%) patients with haematologic complete remission also had minimal residual disease (MRD) responses (defined as MRD by PCR < 1 x 10-4).
Dvaindvajset od 25 (88 %) bolnikov s hematološko popolno remisijo je imelo tudi odzive minimalne rezidualne bolezni (opredeljen kot minimalna rezidualna bolezen s PCR < 1 x 10-4).
Twice (2x)
dvakrat (2x)
twice a day (approximately every 12 hours);
dvakrat na dan (približno vsakih 12 ur);
twice daily
600/100 mg dvakrat na dan N=296
Twice daily
dvakrat na dan
Twice daily
Dvakrat na dan.
Twice daily (N=207)
Dvakrat na dan (N=207)
twice daily by mouth with meals to lower your chance of an upset stomach.
dvakrat na dan skozi usta skupaj s hrano, da se zmanjša možnost želodčnih težav.
Twice Daily Dose
odmerek 250 mg/m2 dvakrat na dan
Twice Daily Dose
odmerek 300 mg/m2 dvakrat na dan
Twice daily dose 350 mg/m²
odmerek 350 mg/m2 dvakrat na dan
Twice daily dosing
Odmerjanje dvakrat na dan
Twice daily oral solution dose (dose in mg)
odmerek dvakrat na dan (odmerek v mg)
Twice daily oral solution dose (dose in mg/kg)
Odmerek peroralne raztopine dvakrat na dan (odmerek v mg/kg)
twice daily regimen should be
dvakrat na dan.
twice daily results in
neželenih učinkov.
Twice daily treatment with 0.03% tacrolimus ointment was more effective than once daily administration (Table 3).
Zdravljenje z 0,03% mazilom s takrolimusom dvakrat na dan je bilo učinkovitejše kot uporaba enkrat na dan (preglednica 3).
twice daily)
dvakrat dnevno)
twice daily.
dvakrat na dan
twice daily/600 mg once daily)
dvakrat na dan/600 mg enkrat na dan)
Twice weekly Bortezomib Accord (cycles 1-4)
Odmerjanje zdravila Bortezomib Accord dvakrat na teden (krogi 1-4)
Twice weekly Bortezomib Hospira (cycles 1-4)
Odmerjanje zdravila Bortezomib Hospira dvakrat na teden (krogi 1-4)
Twice weekly Bortezomib SUN (cycles 1-4)
Odmerjanje zdravila Bortezomib SUN dvakrat na teden (krogi 1–4)
Twice weekly VELCADE (cycles 1-4)
Odmerjanje zdravilaVELCADE dvakrat na teden (krogi 1-4)
Twinrix Adult can also be given as a total of three doses over 1 month.
S cepivom Twinrix za odrasle ste lahko cepljeni tudi z vsemi tremi odmerki v enem mesecu.
Twinrix Adult contains neomycin
Cepivo Twinrix za odrasle vsebuje neomicin
Twinrix Adult has no or negligible influence on the ability to drive and use machines.
Twinrix za odrasle nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Twinrix Adult is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated hepatitis A (HA) virus and purified hepatitis B surface antigen (HBsAg), separately adsorbed onto aluminium hydroxide and aluminium phosphate.
Twinrix za odrasle je kombinirano cepivo, pripravljeno iz posameznih pripravkov prečiščenega, inaktiviranega virusa hepatitisa A (HA) in prečiščenega površinskega antigena virusa hepatitisa B (HBsAg), ki sta ločeno adsorbirana na aluminijev hidroksid in aluminijev fosfat.
Twinrix Adult is a white, slightly milky liquid presented in a glass prefilled syringe (1 ml).
Cepivo Twinrix za odrasle je bela, rahlo mlečna tekočina v stekleni napolnjeni injekcijski brizgi (1 ml).
Twinrix Adult is a white, slightly milky liquid presented in a glass vial (1 ml).
Cepivo Twinrix za odrasle je bela, rahlo mlečna tekočina v stekleni viali (1 ml).
Twinrix Adult is available in packs of 1, 10, and 25.
Cepivo Twinrix za odrasle je na voljo v pakiranjih po 1, 10 in 25.
Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Cepivo Twinrix za odrasle je indicirano za uporabo pri neimunih odraslih in mladostnikih, starih 16 let in več, pri katerih obstaja tveganje za okužbo z virusom hepatitisa A in virusom hepatitisa B.
Twinrix Paediatric
Twinrix za otroke
Twinrix Paediatric can be given concomitantly with Human Papillomavirus (HPV) vaccine.
Cepivo Twinrix za otroke je mogoče uporabiti sočasno s cepivom proti humanemu papilomavirusu (HPV).
Twinrix Paediatric contains neomycin
Cepivo Twinrix za otroke vsebuje neomicin
Twinrix Paediatric has no or negligible influence on the ability to drive and use machines.
Twinrix za otroke nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Twinrix Paediatric is a white, slightly milky liquid presented in a glass prefilled syringe (0.5 ml).
Cepivo Twinrix za otroke je bela, rahlo mlečna tekočina v stekleni napolnjeni injekcijski brizgi (0,5 ml).
Twinrix Paediatric is a white, slightly milky liquid presented in a glass vial (0.5 ml).
Cepivo Twinrix za otroke je bela, rahlo mlečna tekočina v stekleni viali (0,5 ml).
Twinrix Paediatric is available in packs of 1, 3 and 10.
Cepivo Twinrix za otroke je na voljo v pakiranjih po 1, 3 in 10.
Twinrix Paediatric – Suspension for injection
Twinrix za otroke – suspenzija za injiciranje
Twinrix Paediatric – Suspension for injection in prefilled syringe
Twinrix za otroke – suspenzija za injiciranje v napolnjeni injekcijski brizgi
Twinrix Paediatric, Suspension for injection
Twinrix za otroke, suspenzija za injiciranje
Twinrix Paediatric, Suspension for injection in prefilled syringe
Twinrix za otroke, suspenzija za injiciranje v napolnjeni injekcijski brizgi
Twist and pull off Over-cap and Tip-cap.
Obrnite in snemite zunanji pokrov ter pokrovček konice.
Twist clear cartridge slightly in the direction of the arrow to complete the “click” and center the number in the window.
Prozorni vložek rahlo zasukajte v smeri puščice, da boste dosegli "klik" in bo številka na sredi okenca.
Twist clockwise until snugly fitted.
Obračajte jo v desno, dokler ni tesno nameščena.
Twist knob to release injection button.
Zasukajte gumb, da boste sprostili gumb za injiciranje.
Twist off administration syringe from vial adapter.
Odpnite brizgo za injiciranje z nastavka za vialo.
Twist off the base cap.
Odvijte pokrovček ohišja.
Twist off the bottle cap.
Odvijte zamašek s plastenke.
Twist off the bottle cap.
Odvijte zaporko na kapalnem vsebniku.
Twist off the bottle cap.
Odvijte zaporko.
Twist off the cap
Odvijte zaporko.
Twist off the cap (picture 1).
Pokrovček odtrgajte z zavijanjem (slika 1).
Twist off the cap in the direction of the arrows.
Pokrovček zasukajte in potegnite v smeri puščice.
Twist off the cap.
Odvijte zaporko.
Twist pen to mix your medicine
Sukajte peresnik, da boste zmešali zdravilo
Twist pen to prime the needle
Zasučite peresnik, da boste iglo pripravili za uporabo
Twist the reclosable bottle cap adapter onto the bottle.
Na steklenico privijte zamašek z nastavkom za brizgo.
Twist the top of the case in a clockwise direction until it is closed tighly.
Pokrov etuija privijte v smeri urinega kazalca, dokler ni trdno zaprt.
Twist-off base cap
Navojni pokrovček
Twisting of an ovary (ovarian torsion)
zasuk jajčnikov (torzija jajčnikov)
Twitching (B)
trzanje (B)
Two (1%) of the patients had severe reactions; 1 case of pruritus and 1 case of redness.
Pri dveh bolnikih (1 %) so se pojavile hude reakcije – pri enem pruritus in pri drugem rdečica.
Two (2) patients underwent reportedly the rapid elimination procedure; however, the outcome was unknown for both patients.
Po poročanjih sta dva bolnika prestala postopek hitrega izločanja; vendar je bil izid (pri obeh bolnikih) neznan.
Two (2/957, 0.2%) of these tolvaptan treated-patients, as well as a third patient from an extension open label trial, exhibited increases in hepatic enzymes (>3xULN) with concomitant elevations in BT (>2xULN).
Pri dveh (2/957; 0,2 %) od teh bolnikov, zdravljenih s tolvaptanom, in pri tretjem bolniku v podaljšku odprtega preskušanja so se jetrni encimi zvišali (> 3 x ULN) s sočasnim zvišanjem skupnega bilirubina (> 2 x ULN).
Two 10 mg capsules
dve 10 mg kapsuli
Two 10 mg capsules plus one 4 mg capsule
dve 10 mg kapsuli in ena 4 mg kapsula
Two 10 mg tablets
dve 10-miligramski tableti
Two 10 mg tablets once a day
Dve 10 mg tableti enkrat dnevno
two 10 mg tablets once a day
dve 10-miligramski tableti enkrat na dan
two 10 mg tablets or one 20 mg tablet once a day
dve 10 mg tableti ali ena 20 mg tableta enkrat dnevno
Two 10 mg tablets or one 20 mg tablet once a day
dve 10-miligramski tableti ali ena 20-miligramska tableta
Two 12-week paediatric studies have been performed in which 265 children aged 6-11 years were treated with a maintenance dose of budesonide/formoterol (2 inhalations of 80 micrograms
Izvedeni sta bili dve 12-tedenski pediatrični študiji, v katerih je 265 otrok, starih od 6 do 11 let, uporabljalo vzdrževalni odmerek budezonida/formoterola (2 vdiha po
Two 12-week paediatric studies have been performed in which 265 children aged 6-11 years were treated with a maintenance dose of budesonide/formoterol (2 inhalations of 80 micrograms/4.5 micrograms
Izvedeni sta bili dve 12-tedenski pediatrični študiji, v katerih je 265 otrok, starih od 6 do 11 let, uporabljalo vzdrževalni odmerek budezonida/formoterola (2 vdiha po
Two 19-gauge, 50 mm Hypodermic safety needles
Dve 19-gauge, 50 mm podkožni varnostni igli
Two 20-mg vials reconstituted with 1.2 mL solvent each
Dve 20-mg viali, vsaka rekonstituirana z 1,2 ml vehikla
two 200 mg capsules
dve 200 mg kapsuli
Two 320 mg/40 mg tablets a day
Dve 320 mg/40 mg tableti na dan
Two 4 mg capsules
dve 4 mg kapsuli
Two 400 mg capsules (800 mg) - taken three times a day (every 8 hours).
Dve 400 mg kapsuli (800 mg) - vzeti trikrat na dan (vsakih 8 ur).
Two add-on therapy trials, which added either dapagliflozin to saxagliptin plus metformin or saxagliptin to dapagliflozin plus metformin, were also conducted for 24 weeks followed by a 28 week extension treatment period.
Dve preskušanji dodatka zdravljenju – v njih so dodali ali dapagliflozin saksagliptinu in metforminu ali saksagliptin dapagliflozinu in metforminu – sta prav tako trajali 24 tednov, sledilo pa je 28-tedensko obdobje podaljšanega zdravljenja.
Two additional studies looked at the appropriate duration of the infusion for Vimpat solution and compared its safety with that of placebo infusions in a total of 199 patients.
V dveh dodatnih študijah so ugotavljali tudi ustrezno trajanje infundiranja raztopine zdravila Vimpat ter primerjali njegovo varnost z infuzijami placeba pri 199 bolnikih.
Two additional studies looked at the effects of Tracleer dispersible tablets in children: the first study included 36 children with PAH who were aged between two and 11 years, while the second study included 64 children with PAH from three months up to 11 years of age.
V dveh dodatnih študijah so proučevali učinke disperzibilnih tablet zdravila Tracleer pri otrocih: v prvo je bilo vključenih 36 otrok s PAH, starih od dve do 11 let, v drugo pa 64 otrok s PAH, starih od treh mesecev do 11 let.
two alcohol swabs
dva alkoholna zloženca
two alcohol swabs
dva alkoholna zloženca,
two alcohol swabs
dve alkoholni blazinici
two alcohol swabs for single use
2 alkoholna tampona za enkratno uporabo
two alcohol swabs,
dve alkoholni blazinici,
two alcohol swabs, one pre-filled syringe containing the medicinal product
dve alkoholni blazinici napolnjeno injekcijsko brizgo z zdravilom.
two alcohol swabs, one syringe of Zutectra, one needle suitable for subcutaneous injection.
dve alkoholni krpici, eno injekcijsko brizgo zdravila Zutectra, eno iglo, primerno za podkožno injiciranje.
Two children on fluticasone propionate/salmeterol and 5 children on fluticasone propionate withdrew because of worsening asthma.
Dva otroka na flutikazonpropionatu/salmeterolu in 5 otrok na flutikazonproprionatu je zaradi poslabšanja astme izstopilo iz študije.
Two clinical studies were conducted to directly compare liquid and lyophilised formulations of palivizumab.
Dve klinični študiji sta bili izvedeni za neposredno primerjavo palivizumaba v tekoči in liofilizirani obliki.
Two clinically silent, low-titre, transient inhibitors were observed in 94 patients with a median exposure of 76 exposure days (ED, range 1-92), corresponding to 2.2% of the 89 patients with at least 50 ED.
Pri 94 bolnikih z mediano izpostavljenostjo 76 dni izpostavljenosti (exposure days - ED, razpon 1-92) so ugotovili 2 klinično asimptomatska bolnika z nizkimi titri prehodnih inhibitorjev, kar ustreza 2,2 % od 89 bolnikov z vsaj 50 ED.
Two controlled clinical trials with Betaferon involving a total of 1,657 patients with secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i.e. patients were able to walk) were performed.
Izvedeni sta bili dve nadzorovani klinični preskušanji z zdravilom Betaferon, ki sta skupaj vključevali 1657 bolnikov s sekundarno progresivno multiplo sklerozo (izhodiščni EDSS 3 do 6,5, tj. bolniki so lahko hodili).
Two controlled studies (006 and ACTG 364) of approximately one year duration with efavirenz in combination with NRTIs and/or PIs, have demonstrated reduction of viral load below the limit of quantification of the assay and increased CD4 lymphocytes in antiretroviral therapy-naïve and NRTI- experienced HIV-infected patients.
Dve nadzorovani študiji (006 in ACTG 364) z efavirenzem v kombinaciji z NRTI-ji in/ali zaviralci proteaze, ki sta trajali približno eno leto, sta pokazali zmanjšanje virusnega bremena pod mejo določitve testa in povečanje števila CD4 limfocitov pri s HIV okuženih bolnikih, ki še niso dobivali protiretrovirusnih zdravil in tistih, ki so že bili zdravljeni z NRTI-ji.
Two controlled, multicentre, randomised, double blind parallel group, Phase III studies provided the data for Panretin gel in the treatment of index cutaneous lesions of KS (Table 3).
V dveh kontroliranih, multicentričnih, randomiziranih, dvojno slepih študijah faze III s paralelnimi skupinami, so ugotavljali učinkovitost zdravila Panretin gel za zdravljenje indeksiranih kožnih lezij KS (razpredelnica 3).
Two dabrafenib capsule strengths, 50 mg and 75 mg, are available to effectively manage dose modification requirements.
Za učinkovito prilagajanje odmerkov sta na voljo dve jakosti kapsul dabrafeniba, 50 mg in 75 mg.
Two developing tanks and covers
Dva generatorja za razvijanje s pokrovi
Two dogs developed epistaxis that was not associated with thrombocytopenia.
Dva psa sta razvila epistakso, ki ni bila povezana s trombocitopenijo.
Two doses each of 0.5 ml
dva odmerka po 0,5 ml
Two doses each of 0.5 ml.
Dva odmerka po 0,5 ml.
Two doses of vaccine with H5N3 (A/Duck/Singapore/97) strain at 3 different dosages (7.5, 15 and 30 µg HA/dose) were administered three weeks apart.
Dva odmerka cepiva s sevom H5N3 (A/Duck/Singapore/97) so uporabili v presledku treh tednov pri treh različnih odmerkih (7,5; 15 in 30 µg HA/odmerek).
Two doses of Versican Plus DHPPi 3–4 weeks apart from 6 weeks of age.
Dva odmerka Versican Plus DHPPi v razmaku 3–4 tednov od starosti 6 tednov naprej.
Two doses of Versican Plus Pi 3–4 weeks apart from 6 weeks of age.
Dva odmerka Versican Plus Pi v razmaku 3–4 tednov od starosti 6 tednov naprej.
Two double-blind, randomised, placebo-controlled studies in adults with a BMI 28 kg/m2 support the efficacy of orlistat 60 mg taken three times daily in conjunction with a hypocaloric, lower-fat diet.
Dve dvojno slepi, randomizirani, s placebom nadzorovani študiji, izvedeni pri odraslih z ITM ≥ 28 kg/m2 podpirajo učinkovitost zdravila orlistat 60 mg v odmerku trikrat na dan v povezavi z nizkokalorično dieto.
Two embryo-fetal development (EFD) studies were performed in rats at 400, 1200 and
Dve študiji embrio-fetalnega razvoja pri podganah so izvedli z odmerki 400, 1200 in
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1,200 and
Dve študiji embrio-fetalnega razvoja pri podganah so izvedli pri odmerkih 400, 1200 in
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and
Dve študiji embrio-fetalnega razvoja pri podganah so izvedli z odmerki 400, 1.200 in
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and
Dve študiji embriofetalnega razvoja pri podganah so izvedli z odmerki 400, 1200 in
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg
Dve študiji embriofetalnega razvoja pri podganah so izvedli z odmerki 400, 1.200 in 3.600 mg/kg/dan.
Two fertility studies in rats showed effects on the parental generation (decreased food consumption and body weight gain, salivation), but tolvaptan did not affect reproductive performance in males and there were no effects on the foetuses.
Dve študije plodnosti pri podganah sta pokazali učinke na starševsko generacijo (zmanjšan vnos hrane in manjše pridobivanje telesne mase, slinjenje), vendar tolvaptan ni vplival na sposobnost razmnoževanja pri samcih ali učinkoval na plod.
Two field studies were conducted in around 120,000 broiler chickens to evaluate the effects of the vaccine.
Za ocenjevanje učinkov cepiva so izvedli dve terenski študiji pri približno 120 000 pitovnih piščancev.
Two further published studies involving 1,190 patients were carried out with Thyrogen using lower doses of radioactive iodine.
Z zdravilom Thyrogen sta bili opravljeni še dve objavljeni študiji, ki sta vključevali 1 190 bolnikov, pri katerih so uporabili nižje odmerke radioaktivnega joda.
Two further studies compared the effects of Sprycel taken once or twice a day, one in 670 patients with chronic phase CML and the other in 611 patients with advanced phase CML or Ph+ ALL.
V dveh nadaljnjih študijah so primerjali učinke zdravila Sprycel, vzetega enkrat ali dvakrat na dan, pri čemer je v eni študiji sodelovalo 670 bolnikov s KML v kroničnem obdobju, v drugi pa 611 bolnikov s KML v napredovalem obdobju ali Ph-pozitivno ALL.
Two further studies in ovarian, fallopian tube and peritoneal cancers were performed in a total of 845 patients with recurrent cancer (that came back after previous platinum-based chemotherapy).
Poleg tega so izvedli še dve dodatni študiji v zvezi z rakom jajčnikov, jajcevodov in potrebušnice pri skupno 845 bolnikih s ponavljajočim se rakom (ki se je po opravljeni kemoterapiji na osnovi platine ponovil).
Two further studies were carried out in a total of 40 healthy volunteers to show that Cubicin injections are as safe as the infusions, and that they produce similar levels of daptomycin in the blood.
Dve dodatni študiji sta bili izvedeni pri skupno 40 zdravih prostovoljcih, da bi dokazali, da je injiciranje zdravila Cubicin enako varno kot infundiranje ter da povzroča podobne ravni daptomicina v krvi.